HRTX News and Press, Heron Therapeutics Inc. From 10/01/19

SAN DIEGO , Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced...

SAN DIEGO , Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced...

Heron Therapeutics (NASDAQ: HRTX ) has resubmitted its NDA to the FDA for HTX-011, an investigational agent for the management of postoperative pain. The Company anticipates a 6-month review by the FDA. More news on: Heron Therapeutics, Inc., Healthcare stocks news, Read more ...

SAN DIEGO , Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that...

SAN DIEGO , Sept. 25, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced...

Good investors spread their bets across a wide spectrum of assets , which is why this list of picks from top Wall Street investors is so interesting. Not only are some of the smartest people in finance buying these three stocks, but the opportunities highlighted here by big-name investors, note...

Heron Therapeutics ( HRTX -0.5% ) announces  positive results from a Phase 3 clinical trial, EPOCH 2 , evaluating HTX-011 for the management of pain in patients undergoing hernia repair surgery. More news on: Heron Therapeutics, Inc., Healthcare stocks news, Read more ...

SAN DIEGO , Aug. 20, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced tha...

Trust is always a good idea. For someone else. " - Sherrilyn Kenyon Second quarter results continue to hit the wires in a fast and furious manner. Given the recent turmoil in the market, investors can be forgiven for overlooking many good results from small-cap concerns. The market has ha...

Heron Therapeutics (NASDAQ: HRTX ): Q2 GAAP EPS of -$0.63 in-line. Revenue of $36.7M (+112.1% Y/Y) beats by $5.27M . Shares +1% PM. Press Release More news on: Heron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,